Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome.
Plasma exchange (PE) and administration of intravenous immunoglobulin (i.v. IgG) are established treatments for Guillain-Barré syndrome (GBS). Combination treatment with elimination of postulated pathogenetic factors by PE or selective adsorption (SA) treatment and subsequent immunomodulation by intravenous IgG may provide a more effective treatment. In a single-center randomized study, 45 patients with acute GBS were prospectively examined using a clinical score. We treated 11 patients by PE, 13 with SA using a tryptophan-linked polyvinyl alcohol gel adsorbent, and 21 with SA followed by intravenous IgG. The patients treated sequentially by selective adsorption and intravenous IgG improved significantly better than the patients who received plasma treatment only. The results suggest that combination treatment of GBS may be superior to plasma treatment alone.
Department of Neurology, University of Cologne, Germany.
W F
WF
Haupt
C
C
Birkmann
C
C
van der Ven
G
G
Pawlik
D000208:Acute Disease; D003131:Combined Modality Therapy; D006233:Persons with Disabilities; D020275:Guillain-Barre Syndrome / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007163:Immunosorbent Techniques / Q000295:instrumentation; D010951:Plasma Exchange / Q000295:instrumentation / Q000379:methods; D011446:Prospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous